Focus Areas
COVID-19
NeuCovix TM NEUTRALIZING ANTIBODY RAPID DIAGNOSTIC TEST
AXIM Biotechnologies has developed the first-in-class rapid
(10-minute) point-of-care test that measures the concentration of neutralizing antibodies to COVID-19. AXIM believes this rapid test will be useful in identifying the best convalescent plasma for treating patients fighting COVID-19 and for monitoring neutralizing antibodies elicited by COVID-19 vaccines.
DIAGNOSTICS
CANCER DIAGNOSTICS
Using proprietary polyclonal antibodies in collaboration with world-renowned research and academic centers, we have introduced a prototype diagnostic test that measures levels of QSOX1-L in blood and filed for patent protection.
THERAPEUTICS
CLINICAL ONCOLOGY
Through its research collaborations with various academic and medical facilitates, AXIM is working with an enzyme called “QSOX1” in both its clinical and diagnostic research.
Research suggests a chemical compound that inhibits QSOX1 could be an oncology drug. Axim has discovered SBI-183 to be such a drug.